Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 323,800 |
|
|||||
| News | - | ||||||
| Day High | 2.23 | Low High |
|||||
| Day Low | 2.06 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Invivyd Inc | IVVD | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.18 | 8.70% | 2.25 | 23:00:13 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 2.06 | 2.06 | 2.23 | 2.15 | 2.07 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 4,062 | 323,800 | US$ 2.16 | US$ 698,611 | - | 0.9802 - 5.195 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 16:25:45 | 10 | US$ 2.21 | USD |
Invivyd Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 235.65M | 110.11M | - | 0 | -198.64M | -1.80 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Invivyd News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IVVD Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.36 | 2.45 | 2.00 | 2.20 | 899,625 | -0.11 | -4.66% |
| 1 Month | 4.70 | 4.74 | 2.00 | 2.88 | 910,899 | -2.45 | -52.13% |
| 3 Months | 4.71 | 5.10 | 2.00 | 3.76 | 895,583 | -2.46 | -52.23% |
| 6 Months | 1.66 | 5.195 | 1.37 | 3.66 | 1,185,279 | 0.59 | 35.54% |
| 1 Year | 1.11 | 5.195 | 0.9802 | 3.20 | 738,546 | 1.14 | 102.70% |
| 3 Years | 4.70 | 5.195 | 0.9802 | 3.05 | 560,908 | -2.45 | -52.13% |
| 5 Years | 4.70 | 5.195 | 0.9802 | 3.05 | 560,908 | -2.45 | -52.13% |
Invivyd Description
| Invivyd Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's lead product candidate, ADG20 is developed for the treatment and prevention of coronavirus disease which has demonstrated clinically meaningful results in global Phase 3 clinical trials against multiple variants of concern for the prevention and treatment of COVID-19. |
